Chimeric Therapeutics Ltd (ASX:CHM) CEO Jennifer Chow tells Proactive the company has the ethics review board’s green light to initiate a multi-site Phase 1B clinical trial of CHM 1101 in patients with recurrent and/or progressive glioblastoma multiforme (GBM). CHM sees this as a new chapter in the development of CHM 1101, which will see the company roll-out the two-part Phase 1B clinical study across multiple trial sites.
Chimeric Therapeutics thrilled with ethics approval for brain cancer study
